Finland· FI-REL-REL64691

Epclusa

A sofosbuvir and velpatasvir product containing sofosbuvir + velpatasvir, registered in Finland by Paranova Oy. The same ATC class is registered in 16 of our 19 countries.

ATC J05AP55

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedEpclusaATCJ05AP55REGISTER NO.FI-REL-REL64691PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Sofosbuvir and velpatasvir is registered in 16 of 19 countries.

Countries holding a registration under ATC J05AP55 (sofosbuvir and velpatasvir), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 11 of them publish a price we can compare per daily dose

Sofosbuvir and velpatasvir · ATC J05AP55

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Sofosbuvir + Velpatasvir
Manufacturer
Paranova Oy
Country
Finland (FI)
ATC code
J05AP55
ATC class
Sofosbuvir and velpatasvir
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

80 interactions on record for sofosbuvir and velpatasvir.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sofosbuvir and velpatasvir · interactions on record

80 records

  • 14 severe
  • 61 moderate
  • 5 minor

Most severe, free to view

  • OmeprazoleA02BC01severe
  • PantoprazoleA02BC02severe
  • LansoprazoleA02BC03severe
  • RabeprazoleA02BC04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2e72859a-f752-4c36-82d2-aaf9f8d824d7
GET /v1/drugs/2e72859a-f752-4c36-82d2-aaf9f8d824d7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "1",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "ED",
  "strength": "400 mg / 100 mg",
  "atc_label": "sofosbuviiri ja velpatasviiri",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/16/1116/001",
  "fimea_rel_id": "REL64691",
  "authorised_at": "2025-10-24"
}

See everything about sofosbuvir and velpatasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.